Fibrates in the management of atherogenic dyslipidemia
- PMID: 29183206
- DOI: 10.1080/14779072.2017.1408410
Fibrates in the management of atherogenic dyslipidemia
Abstract
Significant advancements in the treatment of hypercholesterolemia have recently been achieved. However, a considerable level of residual cardiovascular risk still affects patients' outcomes. Atherogenic dyslipidemia is one of the major constituents of residual risk. Fibrates, PPAR alpha agonists, which modify lipid profile and have numerous pleiotropic effects, seem to be drugs of choice in patients with atherogenic dyslipidemia. These drugs are effective both in monotherapy and combined therapy with statins. Areas covered: A review of clinical trials and experimental studies on fibrates and their use in the treatment of lipid disorders has been performed. Expert commentary: Fibrates are an effective and safe group of drugs to treat patients with atherogenic dyslipidemia. In this particular population of patients, they improve cardiovascular outcomes. Benefits of fibrate treatment extend beyond the impact of lipid profile. Significant improvements in carbohydrate metabolism, adipokines levels, thrombosis and inflammation were also noted.
Keywords: Fibrates; HDL-cholesterol; PPAR alpha; atherogenic dyslipidemia; triglycerides.
Similar articles
-
Benefits and risks of the treatment with fibrates--a comprehensive summary.Expert Rev Clin Pharmacol. 2018 Nov;11(11):1099-1112. doi: 10.1080/17512433.2018.1537780. Epub 2018 Oct 23. Expert Rev Clin Pharmacol. 2018. PMID: 30328735 Review.
-
[Fibrates in the light of large clinical trials].Pol Merkur Lekarski. 2015 Apr;38(226):222-7. Pol Merkur Lekarski. 2015. PMID: 25938391 Review. Polish.
-
The role of fibrate treatment in dyslipidemia: an overview.Curr Pharm Des. 2013;19(17):3124-31. doi: 10.2174/1381612811319170020. Curr Pharm Des. 2013. PMID: 23317397 Review.
-
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125. Cardiovasc Diabetol. 2012. PMID: 23057687 Free PMC article. Review.
-
Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.Atherosclerosis. 2011 Aug;217(2):492-8. doi: 10.1016/j.atherosclerosis.2011.04.020. Epub 2011 Apr 27. Atherosclerosis. 2011. PMID: 21592479 Review.
Cited by
-
Identification of candidate metabolite biomarkers for metabolic syndrome and its five components in population-based human cohorts.Cardiovasc Diabetol. 2023 Jun 16;22(1):141. doi: 10.1186/s12933-023-01862-z. Cardiovasc Diabetol. 2023. PMID: 37328862 Free PMC article.
-
Therapeutic Effect of Curcumin on 5/6Nx Hypertriglyceridemia: Association with the Improvement of Renal Mitochondrial β-Oxidation and Lipid Metabolism in Kidney and Liver.Antioxidants (Basel). 2022 Nov 6;11(11):2195. doi: 10.3390/antiox11112195. Antioxidants (Basel). 2022. PMID: 36358567 Free PMC article.
-
Lipid Aberrations in Lichen Planus.Metabolites. 2022 Oct 22;12(11):1008. doi: 10.3390/metabo12111008. Metabolites. 2022. PMID: 36355091 Free PMC article. Review.
-
PPAR-α knockout leads to elevated blood pressure response to angiotensin II infusion associated with an increase in renal α-1 Na+/K+ ATPase protein expression and activity.Life Sci. 2022 May 1;296:120444. doi: 10.1016/j.lfs.2022.120444. Epub 2022 Mar 1. Life Sci. 2022. PMID: 35245523 Free PMC article.
-
Transcription Factor-7-Like-2 (TCF7L2) in Atherosclerosis: A Potential Biomarker and Therapeutic Target.Front Cardiovasc Med. 2021 Sep 9;8:701279. doi: 10.3389/fcvm.2021.701279. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34568447 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical